{
    "clinical_study": {
        "@rank": "161605", 
        "arm_group": [
            {
                "arm_group_label": "Accu-Chek FlexLink Plus cross over to Accu-Chek FlexLink", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Accu-Chek FlexLink cross over to Accu-Chek FlexLink Plus", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "German Multi-centered, randomized, crossover study in diabetic patients evaluating two\n      infusion sets under real life conditions at home. Subjects will be randomized to use one of\n      the infusion set devices during the first period of 4 weeks, and be switched to the other\n      infusion set for the second period of 4 weeks."
        }, 
        "brief_title": "A Study Evaluating the Perception of Insertion Pain With Accu-Chek FlexLink and FlexLink Plus Insulin Pump Devices Under Real Life Conditions in Diabetic Patients.", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects at least 18 years of age\n\n          -  Diabetes mellitus type 1 or type 2\n\n          -  Continuous subcutaneous insulin therapy (CSII) for at least 3 months\n\n          -  Insulin pump compatible with Luer lock infusion set (Accu-Chek, Disetronic, Animas,\n             Deltec Cozmo and Minimed 506 to 508)\n\n          -  Sufficient potential infusion sites suitable for the usage of a cannula length of 8\n             mm and a tubing length of 70 and 80 cm\n\n          -  Willing to measure blood glucose at least 4 times per day and 1-3 hrs after each new\n             insertion\n\n          -  Willing and able to participate and comply with study procedures including the\n             general recommendation of shifting infusion sets (at least every 3 days)\n\n        Exclusion Criteria:\n\n          -  Significantly impaired awareness of hypoglycemia\n\n          -  A history of or high risk of ketoacidosis during CSII therapy\n\n          -  Frequent catheter abscesses in the past year, as per investigator\u00b4s discretion\n\n          -  Known strong plaster incompatibility and/or allergy (history of catheter use)\n\n          -  Unstable chronic disease other than diabetes\n\n          -  Chronic use of steroids in adrenal suppressive doses, other immuno-modulatory\n             medication or chemotherapy\n\n          -  Acute illness or abnormality at the time of screening rendering the patient not\n             suitable to participate in the study in the opinion of the Investigator\n\n          -  Chronic use of analgesics and any other condition interfering with the assessment of\n             pain, as per investigator\u00b4s discretion\n\n          -  Are either pregnant or breastfeeding or are currently planning a pregnancy"
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103595", 
            "org_study_id": "RD001494"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Accu-Chek FlexLink Plus cross over to Accu-Chek FlexLink", 
                    "Accu-Chek FlexLink cross over to Accu-Chek FlexLink Plus"
                ], 
                "description": "Insulin pump device used for 4-weeks under real life conditions", 
                "intervention_name": "Accu-Chek FlexLink Plus", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Accu-Chek FlexLink Plus cross over to Accu-Chek FlexLink", 
                    "Accu-Chek FlexLink cross over to Accu-Chek FlexLink Plus"
                ], 
                "description": "Insulin pump device used for 4-weeks under real life conditions", 
                "intervention_name": "Accu-Chek FlexLink", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aschaffenburg", 
                        "country": "Germany", 
                        "zip": "63739"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13597"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "01627"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rostock", 
                        "country": "Germany", 
                        "zip": "18057"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "ULM", 
                        "country": "Germany", 
                        "zip": "89081"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Perception of Insertion Pain With Soft Cannula Infusion Sets: A Multicenter, Randomized, Cross-over Study to Evaluate Accu-Chek FlexLink Plus and Accu-Chek FlexLink Under Real Life Conditions.", 
        "overall_official": {
            "affiliation": "Roche Diagnostics GmbH", 
            "last_name": "Linda Amstutz", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: BfArM"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Perception of pain during infusion set insertion assessed by means of a visual analogue scale (VAS)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103595"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of kinked cannulas", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Pump settings, including insulin dosage", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Device satisfaction/preference as assessed by patient surveys", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Investigator assessment of patient device use", 
                "safety_issue": "No", 
                "time_frame": "At Baseline and Week 4"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Insulin set replacement pattern", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}